NYSE Euronext welcomes Cardio3 BioSciences on its European market


Brussels, 5 July 2013 – Cardio3 BioSciences, a leading Belgian biotechnology specialized in the treatment of cardiac diseases, today celebrated its successful listing on NYSE Euronext (NYX) in Brussels and Paris. Cardio3 BioSciences is the first Belgian company to launch a public offering simultaneously on NYSE Euronext in Brussels and Paris.
Cardio3 BioSciences, headquartered in Mont-Saint-Guibert (Belgium), is a biopharmaceutical company, founded in 2007, and focused on the development  of regenerative, protective, and reconstructive therapies for treating cardiac disorders (primarily heart failure and myocardial infarction).
Cardio3 BioSciences (ticker: CARD) was listed through admission to trading of 4,744,067 existing shares and 1,381,500 new shares  under a Global Offering. The IPO price of Cardio3 BioSciences shares was €16.65 per share, valuing Cardio3 Biosciences at €101.9 million. The operation allowed the company to raise €23 million.
“We are delighted to welcome Cardio3 BioSciences to NYSE Euronext, a market offering growth companies a springboard for business development and enhanced visibility,” said Vincent Van Dessel, Chairman and CEO of NYSE Euronext Brussels. “Cardio3 BioSciences now benefits from the range of solutions offered by its partner NYSE Euronext—solutions that will enable it to raise both its equity and its profile.”
“It is vital for SMEs to be able to raise capital for future growth,” said Alain Baetens, Head of Listings Belgium at NYSE Euronext. “This is the 6th listing of a pure biotechnology company in Brussels, which highlights the importance of financing through the equity market for such innovative companies. Moreover, it strengthens NYSE Euronext’s position as the first venue for biotech companies in Europe with 30 biotech companies listed, representing a total market capitalization of €2.8 billion, out of which 3 Belgian ones in the top 5. ”
“It is with great pride that we announce our listing in Brussels and in Paris,” said Dr Christian Homsy, CEO of Cardio3 BioSciences. “We are the first biotechnology company to list on both exchanges and welcome our new investors both institutional and private individuals. We expect the success of our IPO will allow us to complete our European Phase III study for C-Cure®, a unique cell therapy for the treatment of heart failure which we believe has the potential to mark a significant step forward in treatment for heart failure patients. As part of the IPO, we have secured the continued support of the SRIW Group and a new investment from PMV and look forward to making an on-going contribution to the biotechnology sector in the Walloon Region and in Flanders.”
In order to celebrate this new listing, Christian Homsy, CEO of Cardio3 BioSciences, rang the bell to open trading on NYSE Euronext’s Brussels market.
NYSE Euronext
Jean-Yves Daxhelet
Tel.: +32 (0)2 213 13 03
Cardio3 BioSciences
Anne Portzenheim 
Tel.: +32 (0) 10 39 41 03

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2023, Euronext N.V. - All rights reserved.